Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MHRA Approves New SCM Pharma Commercial Facility

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
SCM Pharma’s new £6m ($10m) pharmaceutical contract manufacturing facility has been given the go ahead.

The UK-based contract development and manufacturing organisation (CDMO) will use its new 26k sq. ft. site for the supply of licensed commercial products and to complement its nearby clinical manufacturing facility for projects requiring scaled-up clinical trial supply quantities.

Based in North-East England, the contract drug manufacturing site is able to handle highly potent, flammable and toxic products along with controlled drugs. It houses technology for aseptic processing and terminal sterilisation capabilities and is equipped for ampoule filling, vial filling and syringe filling.

Dianne Sharp, managing director at SCM Pharma, said: “The official MHRA approval of our new facility is a huge landmark in the history of our company and heralds in a new era for our team.

“I’d like to thank all those involved in the planning, design and construction of SCM Newburn as the end result is what I believe to be one of the finest contract manufacturing facility of its type in Europe.

“We are planning an event to officially open the doors this summer before Newburn becomes a hub for the production and supply of licensed drug products to help patients across the world.”

Independently-owned, SCM Pharma specialises in the sterile manufacturing of drug products that require high containment. Most of the CDMO’s contract filling projects assist companies requiring products for clinical trials or licensed drugs needed in niche commercial markets such as orphan drugs.

With commercial scale cleanrooms, which include a potent suite, dedicated commercial suite and Grade C/D rooms, the new site massively increases SCM Pharma’s current and future capability and capacity.

The site includes a range of packaging and labelling areas, temperature controlled warehousing, raw materials and engineering preparation, visual inspection and leak testing. A dedicated, enclosed cleanroom suite has also been built that houses an automated syringe filling and packaging line with full track and trace capability.

The company’s HQ is dedicated to development and clinical trial supply projects that involve investigational medicinal products and also supports ADME studies requiring the supply of C-14 radiolabeled compounds.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MHRA Approval for CDMO’s Commercial Facility
To supply licensed commercial products and aid clinical projects.
Thursday, June 20, 2013
SCM to Support BTG NDA
Will provide scale up for Varisolve launch.
Friday, April 26, 2013
Vial Filling Boost at SCM
UK-based CDMO invests over £500k in new vial filling equipment.
Thursday, March 15, 2012
SCM to Deliver Vial Filling Project
BrePco selects CDMO to initially produce clinical batches for eight clinical trial sites.
Friday, February 10, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!